Ignite Creation Date:
2024-05-06 @ 7:28 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06024746
Status:
RECRUITING
Last Update Posted:
2024-04-16
First Post:
2023-08-22
Brief Title:
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure CONFIRMATION-HF
Sponsor:
Colorado Prevention Center
Organization:
Colorado Prevention Center
Study Overview
Official Title:
Combined Efficacy and Safety of an Early Intensive Management Strategy With Finerenone and SGLT2 Inhibitor in Patients Hospitalized With Heart Failure CONFIRMATION-HF
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CONFIRMATION
Brief Summary:
Combination therapy with finerenone with empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure
Detailed Description:
This is an international randomized controlled open-label trial of an early intensive management strategy using the combination of finerenone plus sodium-glucose co-transporter 2 inhibitor SGLT2i compared with usual care in patients hospitalized with heart failure HF
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None